Bivalirudin is Cleaved by Thrombin so that there is a Rapid Return to Hemostasis and a Safety Advantage Heparin’s effects on platelets and its reappearance.

Slides:

Advertisements

Similar presentations

Should we use bivalirudin ? Fibrin 2 1 Thrombin 2 1 Thrombin 2 1 Trombina 2 1 Trombina Bivalirudin ADVANTAGES - No requirement for anti-thrombin III -

Advertisements

The Basics of Hemophilia

Drugs for Coagulation Disorders

Heparin in CRRT Benan Bayrakci, McLean Antitrombin 3 Inactive Thrombin (IIa) V, VIII, XIII, Fibrinogen Inactive Factor Xa Common Pathway Inactive.

Blood Clotting Robin Gray.

Major Hemorrhagic Events (Acute Phase) No significant increase in rate of major hemorrhage ESSENCE n = 3171 TIMI 11B n = 3910.

Advanced Slide Set, Slide #1 Contraceptive Implants Advanced Slide Set.

Antithrombin III Independent Anticoagulants Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.

Hypercoagulable States Basic Clinician Training Module 4 Introduction Hypercoagulable States Test Your Knowledge.

Donor deferral due to intake of anti-platelet medication Sharyn Orton, Ph.D. Jaro Vostal, M.D., Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.

Heparin Binds Plasma Proteins: Angiomax ® (Bivalirudin) Binds Specifically to Thrombin Heparin (long strand) binds to other plasma proteins (colored molecules)

Blood – Part 3. Hemostasis  Hemostasis – Stoppage of blood flow.  If a blood vessel wall breaks a series of reactions is set in motion.  This response.

Applications of bivalirudin in interventional cardiology

Compared to Heparin/Enoxaparin with GP IIb/IIa inhibitors,Bivalirudin monotherapy significantly reduces major bleeding while providing similar ischemic.

The Clotting Cascade and DIC Karim Rafaat, MD. Coagulation Coagulation is a host defense system that maintains the integrity of the high pressure closed.

A Randomized Trial of Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Schulman S et al. Proc ASH 2011;Abstract 205.

STEMI < 6 h Lytic eligible Lytic choice by MD (TNK, tPA, rPA, SK) ENOX < 75 y: 30 mg IV bolus SC 1.0 mg / kg q 12 h (Hosp DC) ≥ 75 y: No bolus SC 0.75.

The Biology of Bleeding and Clotting to Death Jeffrey H. Lawson, MD, PhD Director, Vascular Surgery Research Lab Director of Clinical Trials in Vascular.

Dr Jonathan Day Senior Director Global Medical The Medicines Company Bivalirudin Advancing Anticoagulation in ACS.

Anticoagulation to the max A Michael Lincoff MD Cardiologist Division of Cardiology Cleveland Clinic Cleveland, OH.

IS IT HIT OR HAT? M&M Conference 3/28/02. HAT Mild thrombocythopenia 100K- 130K Incidence: 25% 1-4 days after starting heparin Non immune-mediated (direct.

Bivalirudin: Myths vs Reality? Dr Reman McDonagh Nycomed UK Ltd Conflict of Interest: Senior Manager working for Nycomed UK Ltd.

Hemostasis and Coagulation Hemostasis Hemostasis is the maintenance of circulating blood in the liquid state and retention of blood in the vascular system.

Treatment and Prevention of Heparin- Induced Thrombocytopenia Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.

Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.

April 23, 2015 Mini-Lecture Nathan King M.D. Anticoagulation Reversal Part 1: Warfarin.

Www. Clinical trial results.org Heparin Increases Platelet Activation Heparin (yellow strands) makes platelets more reactive to activation by other agonists.

Rationale for the Clinical Evaluation of Combination GP IIb-IIIa Inhibitor and Low-Dose Fibrinolytic Therapy in ST-Elevation Myocardial Infarction.

Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.

Hemostasis Explain the three major steps of Hemostasis.

Bivalirudin Drugbank ID : DB00006

Pharmacotherapy Update for STEMI: What Is New?

William O. Suddath, M. D. Director, Interventional Cardiology Training

Tirofiban Meta-Analysis

Activation of the Hemostatic System During Cardiopulmonary Bypass

Treatment and Prevention of Heparin-Induced Thrombocytopenia

HIT: The Consequences of Heparin’s Nonspecific Binding to Platelet Factor 4 Heparin is neutralized by platelet factor 4, (PF4), which is present in high.

Individuals’ bleeding time measurements (in minutes) plotted against their respective platelet counts. As the straight vertical and diagonal lines show,

Tests for hemostasis (Practical)

…driving discovery An improved potent direct thrombin inhibitor shows efficacy with low bleeding risk Anirban Datta et al.

Improving on Army Field Gauze for Lethal Vascular Injuries: Challenges in Dressing Development J.V. Edwards, D.V. Parikh, P.S. Howley, S.L. Batiste,

Hemodynamic disorders (1 of 3)

Anticoagulation Prepared by Cherie Gan.

Anti-Coagulants Physical Process of Clotting

Indirect vs Direct Thrombin Inhibition

Angiomax® (bivalirudin) Inhibits Clot-Bound Thrombin

New Strategies to Prevent CV Events After Hospital Discharge

Disclaimer. LEGAL AND POLICY CONSIDERATIONS OF NALOXONE FOR OPIOID TOXICITY REVERSAL.

Reversal of Direct Oral Anticoagulants (DOAC)

Effective interprofessional communication is vital when planning surgical procedures for medically complicated individuals on anticoagulants. Thromboembolism.

DiRECT (Diabetes Remission Clinical Trial)

by Jon E. Arnason, Federico Campigotto, Donna Neuberg, and James B

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

UVC UVB A B Supplementary 1, Borrelli et al.

Heparin Binds Plasma Proteins; Angiomax® (bivalirudin) Binds Specifically to Thrombin Heparin (long strand) binds to other plasma proteins (colored molecules)

Antithrombin Therapy in the Management of ACS

Clinical Relevance of Clot Selectivity

C-2. Clinical trial updates: Direct thrombin inhibitors

Significantly enriched phosphorylation motifs from up-regulated phosphopeptides by Motif-X analysis. Significantly enriched phosphorylation motifs from.

Results from the Morris water task.

Parenteral Anticoagulants

Impact of advanced age on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: The.

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

For the HORIZONS AMI Investigators

Platelet cytoplasmic calcium concentration in PI3Kγ-null platelets.

Platelet cytoplasmic calcium concentration in PLCβ2/β3-null platelets.

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction (STEMI) studies; (A) glycoprotein.

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly non-ST segment elevation acute coronary syndrome (NSTE-ACS) studies;

Presentation transcript:

Bivalirudin is Cleaved by Thrombin so that there is a Rapid Return to Hemostasis and a Safety Advantage Heparin’s effects on platelets and its reappearance as it dissociates from cells and proteins may explain the prolonged bleeding risk following discontinuation of heparin, when a return to normal hemostasis is essential. Angiomax® (bivalirudin) is cleaved by thrombin, allowing thrombin to quickly recover hemostatic activity upon discontinuation of Angiomax. The natural reversibility and the short, 25-minute half-life may explain the significantly lower bleeding rates seen in clinical trials. Key Message: The natural reversibility and the short, 25-minute half-life of Angiomax may explain the significantly lower bleeding rates seen in clinical trials. Heparin’s effects on platelets and its reappearance as it dissociates from cells and proteins may explain the prolonged bleeding risk following discontinuation of heparin, when a return to normal hemostasis is essential. Angiomax has a short half-life. It is actually cleaved by thrombin, allowing thrombin to quickly recover hemostatic activity upon discontinuation of Angiomax. Angiomax Prescribing Information, June 14 2005. Maraganore JM et al. Biochemistry. 1990;29:7095-7101. Hirsh J et al. Chest. 2001;119(1 suppl):64S-94S.